



Application of the CARE guideline as reporting standard in the *Biotarget*

Editorial Office

AME Publishing Company

Correspondence to: Editorial Office, AME Publishing Company. Email: biotarget@amegroups.com.

Received: 16 October 2019; Accepted: 30 October 2019; Published: 13 December 2019.

doi: [10.21037/biotarget.2019.10.01](https://doi.org/10.21037/biotarget.2019.10.01)

View this article at: <http://dx.doi.org/10.21037/biotarget.2019.10.01>

The *Biotarget* welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, the *Biotarget* will apply the CARE guidelines (1) as reporting standards for case reports starting from October 14, 2019. For any submission of case report after the date:

- (I) The author should prepare the manuscript according to the CARE guideline and indicate at the end of the Introduction section that the case report is presented in accordance with the CARE Guideline. The wording of the indication could be “We present the following case in accordance with the CARE guideline”. For the example, please refer to the article “Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under *Viscum album* and *Helleborus niger* extracts—a case report” (2).
- (II) The CARE checklist (3) should be provided as an additional file. Submissions received without the Checklist will be returned to the authors as incomplete. The checklist will not be employed as a norm for judging the suitability of manuscripts for publication, but it is intended as an aid to authors to entirely and transparently let reviewers and readers know what authors did and found.

For more detailed information, please refer to the journal’s author instruction.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Biotarget*. The article did not undergo external peer review.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and elaboration document. *J Clin Epidemiol* 2017;89:218-35.
2. Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under *Viscum album* and *Helleborus niger* extracts—a case report. *J Thorac Dis* 2017;9:E1064-70.
3. CARE Checklist. Available online: <https://cdn.amegroups.cn/static/public/system/application/CARE-checklist-English.pdf>

doi: [10.21037/biotarget.2019.10.01](https://doi.org/10.21037/biotarget.2019.10.01)

Cite this article as: Editorial Office. Application of the CARE guideline as reporting standard in the *Biotarget*. *Biotarget* 2019;3:22.